In a randomized controlled trial (RCT) on MASH patients, telmisartan activated PPAR-γ and reduced blood TG and total cholesterol to alleviate the HOMO-IR, steatosis, inflammation, and hepatic fibrosis [172]. This evidence concerns the gene PPARG and steatosis.